Hereditary Spherocytosis — the most common inherited hemolytic anemia in Northern Europeans, where the specific gene variant determines whether the patient needs lifelong transfusions, splenectomy, or only monitoring.
Whole genome sequencing evaluates all five hereditary spherocytosis genes — ANK1, SLC4A1, SPTB, EPB41, and EPB42 — providing the molecular diagnosis that predicts disease severity and guides the splenectomy decision.
Hereditary Spherocytosis
Hereditary spherocytosis (HS) is the most common inherited hemolytic anemia in populations of Northern European descent, with a prevalence of approximately 1 in 2,000-5,000. HS is caused by pathogenic variants in genes encoding red blood cell membrane skeleton proteins: ANK1 (ankyrin-1, ~40-65% of cases), SLC4A1 (band 3/AE1, ~15-25%), SPTB (β-spectrin, ~15-30%), EPB41 (protein 4.1), and EPB42 (protein 4.2). These structural protein deficiencies weaken the vertical connections between the lipid bilayer and the underlying spectrin-actin skeleton, causing progressive membrane vesiculation that transforms the normally biconcave disc-shaped red cell into a spherocyte.
Spherocytes are less deformable than normal red cells and cannot traverse the splenic sinusoidal slits — they are selectively trapped and destroyed in the spleen, producing chronic extravascular hemolysis. Clinical severity ranges from compensated hemolysis (mild anemia, reticulocytosis, indirect hyperbilirubinemia) to transfusion-dependent severe anemia. Complications include chronic jaundice, pigment gallstones (often requiring cholecystectomy by early adulthood), aplastic crises triggered by parvovirus B19 infection, and splenomegaly. HS is often diagnosed in childhood during evaluation for anemia, jaundice, or an incidentally discovered enlarged spleen.
Splenectomy eliminates the site of spherocyte destruction and effectively cures the hemolytic anemia — but carries lifelong infection risk from encapsulated organisms (Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae), requiring pre-splenectomy vaccination, post-splenectomy antibiotic prophylaxis, and patient education about overwhelming post-splenectomy infection (OPSI). The decision to proceed with splenectomy depends heavily on disease severity. ANK1 variants tend to cause moderate-to-severe HS more frequently, while SLC4A1 variants more often cause mild disease. Molecular genotyping provides prognostic information that supplements the clinical severity assessment.
Parvovirus B19 infection causes aplastic crisis in HS patients — red cell production ceases for 7-10 days, dropping hemoglobin precipitously. This is a medical emergency in patients with chronic hemolysis who depend on high reticulocyte production.
Osmotic fragility testing diagnoses HS but does not identify which gene is affected. The specific gene predicts disease trajectory and informs whether splenectomy will be needed — critical for surgical counseling in childhood.
ANK1 variants predict more severe disease — knowing the gene guides the splenectomy decision timeline
ANK1 pathogenic variants are associated with moderate-to-severe HS more frequently than SLC4A1 or SPTB variants. For a child newly diagnosed with HS who currently has compensated hemolysis, knowing whether the causative variant is in ANK1 or SLC4A1 provides prognostic information: ANK1-associated disease is more likely to require splenectomy by adolescence, while SLC4A1-associated disease may remain manageable with folic acid supplementation and observation alone. This genotype-severity correlation supplements clinical monitoring and helps families plan.
HS can be confused with autoimmune hemolytic anemia — molecular diagnosis prevents inappropriate immunosuppressive therapy
Hereditary spherocytosis and warm autoimmune hemolytic anemia (AIHA) both present with spherocytes on the peripheral blood smear, elevated indirect bilirubin, and reticulocytosis. The treatments are entirely different: HS requires splenectomy for severe disease; AIHA requires corticosteroids and immunosuppression. The direct antiglobulin test (DAT/Coombs test) usually distinguishes them, but can be equivocal. Molecular confirmation of an HS-causing variant in ANK1, SLC4A1, or SPTB definitively establishes the diagnosis as inherited membrane disease, eliminating autoimmune hemolysis from the differential and preventing inappropriate immunosuppressive treatment.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Hereditary Spherocytosis and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
